Text Size

Prediction of Visual Field Progression in Patients with Primary Open-Angle Glaucoma, Mainly Including Normal Tension Glaucoma

Nitta K., Wajima R., Tachibana G., Inoue S., Ohigashi T., Otsuka N., Kurashima H., Santo K., Hashimoto M., Shibahara H., Hirukawa M., Sugiyama K.


  • 2017
  • Scientific Reports
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Post-Approval studies/RWE

  • Affiliations

    Fukui-ken Saiseikai Hospital, Fukui, Japan; Kanazawa University Graduate School of Medical Science, Kanazawa, Japan; Crecon Medical Assessment Inc., Tokyo, Japan; Santen Pharmaceutical Co. Ltd., Osaka, Japan

Related Publications

Associations between Clustered Visual Field Progression and Locations of Disc Hemorrhages in Glaucoma: A Three-year Prospective Study

Akagi T.; Fukuchi T.; Higashide T.; Udagawa S.; Ohkubo S.; Sugiyama K.; Tanihara H.; Araie M.; Tomita G.; Matsumoto C.; Tomidokoro A.; Hangai M.; Kawata H.; Inai M.; Tanaka Y.; SVF Prospector Study Group


Proteome-Wide Analysis of Autoantibodies in Open-Angle Glaucoma in Japanese Population: A Pilot Study

Takada N.; Ishikawa M.; Sato K.; Kunikata H.; Ninomiya T.; Hanyuda A.; Fukuda E.; Yamaguchi K.; Ono C.; Kirihara T.; Shintani C.; Tsusu C.; Osanai A.; Goshima N.; Izumi Y.; Zorumski C.F.; Nakazawa T.


Bioequivalence of Preservative-free and Preserved Omidenepag Isopropyl (OMDI) 0.002% Ophthalmic Solutions in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Results from the Phase 3 DAISY Study

Aihara M.; Lu F.; Ikeda T.; Odani-Kawabata N.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022